Bromo-phenyl substituted thiazolyl dihydropyrimidines

Abstract

This invention relates to a bromo-phenyl substituted thiazolyl dihydropyrimidine, its preparation method and use as a medicament for treating and preventing hepatitis B infections. The invention also relates to a composition comprising the dihydropyrimidine, one or more antiviral agents and, optionally, an immunomodulator for treating and preventing HBV infections.

The invention claimed is: 
     
       1. A methanesulfonate salt of a compound having the following structure, or an enantiomer, a levo isomer or a tautomer thereof: 
       
         
           
           
               
               
           
         
       
     
     
       2. A method of preparing the methanesulfonate salt of  claim 1 , wherein the method is characterized by:
 (a) reacting a benzaldehyde having formula (II) with a β-ketoester having formula (III) to produce a benzylidene compound having formula (IV): 
 
       
         
           
           
               
               
           
         
         
           and 
         
         (b) reacting the benzylidene compound having formula (IV) with a salt of an amidine having formula (V): 
       
       
         
           
           
               
               
           
         
         wherein R 1  is o-bromine, R 2  is p-fluorine, R 3  is ethyl, R 6  is thiazolyl-2-yl, X is methylene, and Z is morpholinyl, and wherein the salt is methanesulfonate. 
       
     
     
       3. A method of preparing the methanesulfonate salt of  claim 1 , wherein the method is characterized by reacting a compound having formula (III) with an aldehyde having formula (II) and a salt of an amidine having formula (V), 
       
         
           
           
               
               
           
         
         wherein R 1  is o-bromine, R 2  is p-fluorine, R 3  is ethyl, R 6  is thiazolyl-2-yl, X is methylene, and Z is morpholinyl, and wherein the salt is methanesulfonate. 
       
     
     
       4. A method of preparing the methanesulfonate salt of  claim 1 , wherein the method is characterized by reacting the compound having formula (VI) with a salt of morpholine (VII): 
       
         
           
           
               
               
           
         
         wherein Y is a nucleophilic substituent, and R 1  is o-bromine, R 2  is p-fluorine, R 3  is ethyl, and R 6  is thiazolyl-2-yl, and wherein the salt is methanesulfonate. 
       
     
     
       5. A method of preparing the methanesulfonate salt of  claim 1 , which is characterized by the step of reacting a compound having formula (II) with an aldehyde having formula (X) and a salt of an amidine having formula (V): 
       
         
           
           
               
               
           
         
         wherein R 1  is o-bromine, R 2  is p-fluorine, R 3  is ethyl, R 6  is thiazolyl-2-yl, X is methylene, and Z is morpholinyl, and wherein the salt is methanesulfonate salt. 
       
     
     
       6. A pharmaceutical composition comprising:
 A) the methanesulfonate salt of  claim 1 ; 
 B) at least an HBV antiviral agent; and, when appropriate, 
 C) at least an immunomodulator or an interferon. 
 
     
     
       7. The pharmaceutical composition of  claim 6 , wherein the component B is an HBV polymerase inhibitor, lamivudine or a phenylpropenamide compound having the following formula: 
       
         
           
           
               
               
           
         
       
       or a salt thereof, wherein
 each of R 1  and R 2  is independently C 1-4  alkyl or, together with the nitrogen atom on which they are located, form a ring having 5 to 6 ring atoms which comprise carbon and/or oxygen; and 
 each of R 3  to R 12  is independently hydrogen, halogen, C 1 -C 4 -alkyl, optionally substituted C 1 -C 4 -alkoxy, nitro, cyano or trifluoromethyl; and 
 X is halogen or optionally substituted C 1-4 alkyl. 
 
     
     
       8. The pharmaceutical composition of  claim 7 , wherein the component B is the phenylpropenamide compound having the following structure: 
       
         
           
           
               
               
           
         
       
     
     
       9. A pharmaceutical composition comprising the methane-sulfonate salt of  claim 1 , and, when appropriate, a pharmaceutically acceptable carrier. 
     
     
       10. A medicament comprising at least one pharmaceutical composition of  claim 6 , and, when appropriate, one or more active pharmaceutical agents. 
     
     
       11. A method for treating hepatitis B infection or a disease caused by hepatitis B infection, which comprises administering the methanesulfonate salt of  claim 1  to a patient having the disease. 
     
     
       12. The method of  claim 11 , wherein the method is for treating the disease caused by hepatitis B infection selected from hepatitis, cirrhosis or hepatocellular carcinoma. 
     
     
       13. A method for treating hepatitis B infection or a disease caused by hepatitis B infection, which comprises administering the pharmaceutical composition of  claim 6  to a patient having the disease. 
     
     
       14. A method for treating hepatitis B infection or a disease caused by hepatitis B infection, which comprises administering the pharmaceutical composition of  claim 7  to a patient having the disease. 
     
     
       15. A method for treating hepatitis B infection or a disease caused by hepatitis B infection, which comprises administering the pharmaceutical composition of  claim 8  to a patient having the disease. 
     
     
       16. The method of  claim 13 , wherein the method is for treating the disease caused by hepatitis B infection selected from hepatitis, cirrhosis or hepatocellular carcinoma. 
     
     
       17. The method of  claim 14 , wherein the method is for treating the disease caused by hepatitis B infection selected from hepatitis, cirrhosis or hepatocellular carcinoma. 
     
     
       18. The method of  claim 15 , wherein the method is for treating the disease caused by hepatitis B infection selected from hepatitis, cirrhosis or hepatocellular carcinoma.